Medical/Pharmaceuticals
SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes
BOSTON and ROLLE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an expansion of its partnership with AstraZeneca (LSE/STO/Nasdaq: AZN). This new, multi-year collab...
Sunshine Lake Pharma Co., Ltd. (06887.HK) Completes Listing, Market Capitalisation Expected to Rapidly Surpass RMB 50 Billion
GUANGZHOU, China, Aug. 5, 2025 /PRNewswire/ -- Sunshine Lake Pharma Co., Ltd. (06887.HK) announced that the company will officially list on the Hong Kong Stock Exchange onAugust 7th. Through this integration, the company has effectively combined its expertise in drug R&D with the mature nationwid...
Chugai Pharma Taiwan Honored at the AREA 2025 for its Social Empowerment and Green Innovation
BANGKOK, Aug. 4, 2025 /PRNewswire/ -- Chugai Pharma Taiwan (CPT), a subsidiary of Chugai Pharmaceutical Co., Ltd. inJapan, has been recognized in both the Social Empowerment and Green Leadership categories at the Asia Responsible Enterprise Awards (AREA) 2025. These recognitions highlight the com...
Smart Jelly for Smart Aging: Chula's High-Protein Pudding Takes Global Stage
BANGKOK, Aug. 5, 2025 /PRNewswire/ -- Chulalongkorn University
LA ROCHE-POSAY AND GLOBAL SKIN HEALTH EXPERTS UNITE TO WARN ABOUT LONG TERM CONSEQUENCES OF DANGEROUS 'BURN LINES' SOCIAL MEDIA TREND
PARIS, Aug. 5, 2025 /PRNewswire/ -- A viral TikTok challenge known as "Burn Lines" or "Sunburn Tattoos" is gaining alarming traction among teenagers and young adults worldwide. The trend, which involves placing tape or stencils on the skin to intentionally burn patterned tan lines, has sparked wi...
Minaris Advanced Therapies Opens New State-of-the-Art GMP Facility to Support Global Cell and Gene Therapy Growth
MUNICH, Aug. 4, 2025 /PRNewswire/ -- Minaris Advanced Therapies, a leading global contract development and manufacturing organization and testing provider, has announced the opening of its new GMP manufacturing facility in Munich, Germany. The facility, located in Taufkirchen, strengthens Minaris...
Breaking Through Core CT Technology Barriers!
World-Class Innovations to Debut at 2025 Medtec in September SHANGHAI, Aug. 4, 2025 /PRNewswire/ -- A quiet revolution is underway in the field of high-end medical equipment, led byChina's growing innovation power. Core CT technologies, once dominated byinternational giants, are now being steadi...
NX Taiwan Awarded Healthy Workplace Certification by "Ministry of Health and Welfare"
- Received High Praise for Promoting Health Management and Contributing to Local Communities - TOKYO, Aug. 4, 2025 /PRNewswire/ -- Nippon Express (Taiwan) Co., Ltd. (hereinafter "NX Taiwan"), a group company of NIPPON EXPRESS HOLDINGS, INC., has been accorded Healthy Workplace Certification by t...
Raytone Biotech Announces First Patient Dosed in Clinical Trial of RTP-008 for Dry Eye Disease
BEIJING, Aug. 4, 2025 /PRNewswire/ -- Raytone Biotech, a biotechnology company dedicated to innovative ophthalmic therapies, announced that it successfully completed the first patient dosing in its clinical trial of RTP-008 during Q2 2025. RTP-008 is a bioabsorbable tacrolimus lacrimal canalic...
Alphamab Oncology Announces IND Application for Innovative PD-L1/αvβ6 Bispecific ADC JSKN022 was Officially Accepted by CDE
SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN022, an independently developed innovative bispecific antibody-drug conjugate (ADC) targeting PD-L1 and integrin αvβ6, has been officially acce...
Alveolus Bio Secures Strategic Investment from Shilpa Medicare to Advance Groundbreaking Pulmonary Therapeutics
Shilpa Medicare Serves as Lead Investor, Positioning Alveolus Bio for Phase 2
Clinical Trials and First-in-Human Studies
CAMBRIDGE, Mass. and BIRMINGHAM, Ala. and RAICHUR, India, Aug. 4, 2025
/PRNewswire/ --Alveolus Bio
First Subject Enrolled in Phase 1 Clinical Trial for Luye Pharma's Investigational Antidepressant Targeting NET/DAT/GABAAR
SHANGHAI, Aug. 3, 2025 /PRNewswire/ -- Luye Pharma Group today announced that the first subject has been enrolled in a Phase 1 clinical trial inChina for its LY03021, which was filed throughChina's Class 1 pathway for innovative drugs. LY03021 is an inhibitor of the norepinephrine transporter (NE...
Everest Medicines Expands Strategic Investment in I-MAB
- Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash in I-Mab. Inclusive of I-MAB shares already held by Everest, the pro forma ownership will be 16.1%. - I-Mab's Claudin 18.2 x 4-1BB bispecific antibody, givastomig, demonstrated an impressive overall resp...
ASPIRE for Lung Cancer launches the APAC Lung Cancer Policy Consensus as a regional call to action for improved lung cancer care
SINGAPORE, Aug. 1, 2025 /PRNewswire/ -- On 31st July 2025, a unified consensus document for improving lung cancer care in theAsia-Pacific (APAC) region was officially launched inSingapore, marking a pivotal moment in the regional fight against lung cancer. This represents the first comprehensive ...
Herbalgy Trophy Wraps Up with a Thrilling 1-0 Victory Tottenham for Over Arsenal
Football Fever Grips Hong Kong as nearly 50,000 Fans Pack Kai Tak
Download high-resolution images: http://bit.ly/45dBPVk
Norgine welcomes PBS listing in Australia of IFINWIL® (eflornithine) for patients with high-risk neuroblastoma (HRNB)
This news is for Australian Media only * Eflornithine is now reimbursed by the government under Australia's Pharmaceutical Benefits Scheme (PBS). The Pharmaceutical Benefits Advisory Committee (PBAC) recommended the listing of eflornithine for post-maintenance treatment to prevent relapse in p...
NYSE Content Advisory: Pre-market update + Figma valued at over $19 billion in IPO
NEW YORK, July 31, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content Advisory: Pre-market update + Figma valued at over ...
RESEARCH ADVANCES FROM THE 2025 ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE
TORONTO, July 31, 2025 /PRNewswire/ -- New research results reported at the Alzheimer's Association International Conference® 2025 (AAIC®) advanced scientific understanding of risk, diagnosis and treatment of Alzheimer's disease and other dementias. Highlights include: * Two lifestyle interven...
Alphamab Oncology Announces Anti-HER2 Biparatopic ADC JSKN003 Received U.S. FDA IND Approval to Initiate a Phase II Clinical Study for Platinum-Resistant Ovarian Cancer
SUZHOU, China, July 31, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has received approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical study inthe United States (study n...
Eviva Partners Launches New Think Tank, Exposes Attack on Aluminum-Containing Vaccines
NEW YORK, July 31, 2025 /PRNewswire/ -- Eviva Partners, a nonprofit organization dedicated to strengthening public understanding of medical evidence, is proud to announce the launch ofProtecting Our Health (POH), a new think tank that brings together international experts in communication, public...
Week's Top Stories
Most Reposted
Agoda Releases AI Developer Report 2026: Agentic AI Adoption Outpaces Enterprise Readiness Across Southeast Asia and India
[Picked up by 294 media titles]
2026-09-24 10:30Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 278 media titles]
2026-09-29 09:00HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 278 media titles]
2026-09-28 23:04Malaysia Calls for Shift from Halal-Certified to Halal-Competitive as ASEAN Targets USD5 Trillion Global Halal Economy
[Picked up by 277 media titles]
2026-09-25 14:45Nuix Recognised as a RiskTech100® 2027 Disruptor by Chartis Research
[Picked up by 274 media titles]
2026-09-25 08:30